EGFR and colorectal carcinoma: To this end, however, predictive molecular biomarkers to stratify cancer patients for treatment are available in exceptional cases only (e.g., absence of oncogenic KRAS mutations as a prerequisite for treatment of CRC patients with anti-EGFR antibodies [12]).